Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII

Published on 2020-05-22T17:37:03Z (GMT) by
<div><p>Human coagulation factor VIII (FVIII) is a key co-factor in the clotting cascade, the deficiency of which leads to Hemophilia A. Human plasma-derived (pdFVIII) and recombinant FVIII (rFVIII) had been used as effective products to prevent and treat bleeding episodes. Both FVIII products share identical amino acid sequences and appear to be equivalent as of clinical efficiency. However, systemic reviews found an increased risk of neutralizing antibody (or inhibitor) development with recombinant products. FVIII is a highly glycosylated protein, and its glycosylation pattern is specific to host cells and environments. The roles of glycosylation in immune responses toward pdFVIII and rFVIII are yet to be defined. Herein, we systemically profiled <i>N</i>- and <i>O</i>-glycomes of pdFVIII and rFVIII using a mass spectrometry-based glycoproteomic strategy. A total of 110 site-specific <i>N</i>-glycopeptides consisting of 61 <i>N</i>-glycoforms were identified quantitatively from rFVIII and pdFVIII. Additionally, 31 <i>O</i>-glycoforms were identified on 23 peptides from rFVIII and pdFVIII. A comprehensive comparison of their site-specific glycan profiles revealed distinct differences between the glycosylation of pdFVIII and rFVIII.</p></div>

Cite this collection

Qu, Jingyao; Ma, Cheng; Xu, Xiao-Qian; Xiao, Min; Zhang, Junping; Li, Dong; et al. (2020): Comparative glycosylation mapping of plasma-derived and recombinant human factor VIII. PLOS ONE. Collection. https://doi.org/10.1371/journal.pone.0233576